Eli Lilly CFO leaves after "exhibiting poor judgment"

Josh Smiley, CFO at Eli Lilly, leaves the company after a having "exhibited poor judgment" in a relationship to a colleague, according to the US pharmaceutical giant in a Tuesday announcement. His replacement has been instated.

Photo: Mike Blake/Reuters/Ritzau Scanpix

Eli Lilly's Chief Financial Officer Josh Smiley steps down from Eli Lilly following accusations of an inappropriate relationship between him and an employee, according to a Tuesday press release.

Anat Ashkenazi takes over his position as CFO. Most recently, she served as controller and CFO at Lilly Research Laboratories.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs